BR0016347A - Oligonucleotìdios antisenso - Google Patents

Oligonucleotìdios antisenso

Info

Publication number
BR0016347A
BR0016347A BR0016347-3A BR0016347A BR0016347A BR 0016347 A BR0016347 A BR 0016347A BR 0016347 A BR0016347 A BR 0016347A BR 0016347 A BR0016347 A BR 0016347A
Authority
BR
Brazil
Prior art keywords
antisense oligonucleotides
inhibiting
expression
effective
wild type
Prior art date
Application number
BR0016347-3A
Other languages
English (en)
Inventor
Rajinder Beri
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0016347A publication Critical patent/BR0016347A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"OLIGONUCLEOTìDIOS ANTISENSO". A presente invenção proporciona oligonucleotídios antisenso que são efetivos na inibição da expressão de um gene COL1A1 do tipo selvagem.
BR0016347-3A 1999-12-15 2000-12-12 Oligonucleotìdios antisenso BR0016347A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9929487.8A GB9929487D0 (en) 1999-12-15 1999-12-15 Antisense oligonucleotides
PCT/GB2000/004741 WO2001044455A2 (en) 1999-12-15 2000-12-12 Antisense oligonucleotides for the inhibition of expression of type i procollagen

Publications (1)

Publication Number Publication Date
BR0016347A true BR0016347A (pt) 2002-09-10

Family

ID=10866254

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016347-3A BR0016347A (pt) 1999-12-15 2000-12-12 Oligonucleotìdios antisenso

Country Status (17)

Country Link
US (1) US7173122B2 (pt)
EP (3) EP2025752A3 (pt)
JP (1) JP2003516752A (pt)
KR (1) KR20020064936A (pt)
CN (1) CN1423695A (pt)
AT (2) ATE309338T1 (pt)
AU (1) AU2529701A (pt)
BR (1) BR0016347A (pt)
CA (1) CA2390674A1 (pt)
DE (2) DE60023943T2 (pt)
GB (1) GB9929487D0 (pt)
IL (1) IL149640A0 (pt)
MX (1) MXPA02005871A (pt)
NO (1) NO20022799D0 (pt)
NZ (1) NZ519008A (pt)
WO (1) WO2001044455A2 (pt)
ZA (1) ZA200203878B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396823B2 (en) * 1999-12-15 2008-07-08 Nath Rahul K Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis
CN111378657B (zh) * 2018-12-28 2024-03-15 苏州瑞博生物技术股份有限公司 抑制COL1A1基因表达的siRNA、含有该siRNA的药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265157B1 (en) * 1991-12-03 2001-07-24 Allegheny University Of The Health Sciences Compositions and methods for detecting altered COL1A1 gene sequences
WO1993011149A1 (en) 1991-12-03 1993-06-10 Thomas Jefferson University Methods of detecting a genetic predisposition for osteoporosis
WO1994011494A1 (en) 1992-11-09 1994-05-26 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
CA2159195A1 (en) * 1993-03-26 1994-10-13 Darwin J. Prockop Use of a col 1a1 mini-gene construct to inhibit collagen synthesis
DE59607750D1 (de) * 1995-03-13 2001-10-31 Aventis Pharma Gmbh Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19508923A1 (de) * 1995-03-13 1996-09-19 Hoechst Ag Phosphonomonoesternukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0736608A1 (de) * 1995-04-08 1996-10-09 Roche Diagnostics GmbH Verfahren zur spezifischen Vervielfältigung und zum Nachweis von DNA bzw. RNA
EP0856579A1 (en) * 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH An antisense oligonucleotide preparation method
US6238921B1 (en) 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
BR0015507A (pt) * 1999-11-12 2002-10-22 Fibrogen Inc Gelatinas e colágenos animais

Also Published As

Publication number Publication date
MXPA02005871A (es) 2002-10-23
EP1698695A2 (en) 2006-09-06
DE60023943D1 (de) 2005-12-15
EP1698695B1 (en) 2008-10-08
KR20020064936A (ko) 2002-08-10
WO2001044455A2 (en) 2001-06-21
EP1244781A2 (en) 2002-10-02
NZ519008A (en) 2004-04-30
GB9929487D0 (en) 2000-02-09
ATE410510T1 (de) 2008-10-15
CA2390674A1 (en) 2001-06-21
US7173122B2 (en) 2007-02-06
ATE309338T1 (de) 2005-11-15
DE60023943T2 (de) 2006-08-03
AU2529701A (en) 2001-06-25
EP2025752A2 (en) 2009-02-18
WO2001044455A3 (en) 2002-01-10
EP2025752A3 (en) 2009-08-12
EP1698695A3 (en) 2007-02-14
US20030105050A1 (en) 2003-06-05
NO20022799L (no) 2002-06-12
JP2003516752A (ja) 2003-05-20
ZA200203878B (en) 2003-08-15
DE60040495D1 (de) 2008-11-20
EP1244781B1 (en) 2005-11-09
CN1423695A (zh) 2003-06-11
NO20022799D0 (no) 2002-06-12
IL149640A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
DK1569661T3 (da) Antisense design
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
ATE221914T1 (de) Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung
EP1009860A4 (en) INHIBITION OF THE RAS GENE USING ANTISENSE OLIGONUCLEOTIDES
EP1569695A4 (en) ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
DE50214715D1 (de) Synthetische doppelsträngige oligonucleotide zur gezielten hemmung der genexpression
NO983716D0 (no) Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
ATE216705T1 (de) Antisense-oligonukleotidmodulation der raf- genexpression
ATE428780T1 (de) Verfahren zur zubereitung von antisense oligonukleotiden
ATE317007T1 (de) Gene des 1-desoxy-d-xylulose-biosynthesewegs
EP1142591A4 (en) gene carriers
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
TR199802648A3 (tr) Gen tedavisi için nüklein asit yapilari.
ZA200005409B (en) New nucleotide sequences which code for the eno gene.
GB9929487D0 (en) Antisense oligonucleotides
EP1076093A4 (en) SAKARANETIN SYNTHASE GENE
NO20015330D0 (no) Ny promoter for genekspresjon
GB0218803D0 (en) Targeted gene modification by single-standed DNA oligonucleotides
DE69932331D1 (de) Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit
EP1215284A4 (en) TSG-LIKE GENES
IT1313568B1 (it) Microrganismi fago-resistenti e determinanti genetiche di fago-resistenza.
ITBO20000111V0 (it) Mangiatoia per gabbia o voliera .
ZA200208218B (en) An isolated nucleotide sequence and transgenic organism containing said sequence.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]